SGLT2i increased the plasma fasting glucagon level in patients with diabetes: a meta-analysis

In conclusion, our result indicated SGLT2i intervention would increase the plasma fasting glucagon level in patients with diabetes mellitus. The increase in plasma fasting glucagon level may be associated with reduced insulin level. The increased glucagon-insulin ratio after the use of SGLT2i may make diabetic patients susceptible to ketosis.PMID:33957085 | DOI:10.1016/j.ejphar.2021.174145

Source: European Journal of Pharmacology - May 6, 2021 Category: Drugs & Pharmacology Authors: Xingyun Zhu Chu Lin Li Li Suiyuan Hu Xiaoling Cai Linong Ji Source Type: research